免疫治疗在恶性肿瘤辅助治疗方面的重要作用已引起国际上的密切关注，但尚无结肠癌有效免疫治疗的报道。本项目申请人在国际上首次鉴定和报告了PLAC1/CP1是一类新的肿瘤特异性抗原，前期体外研究证明该基因是结直肠癌免疫治疗的理想靶基因，并鉴定出四段HLA-A*0201 多肽表位作为候选治疗靶点，但PLAC1/CP1抗原疫苗对于体内实体瘤的疗效和分子免疫学作用机制有待阐明。本项目通过建立人免疫重建的小鼠肠癌模型，应用新型PLAC1/CP1抗原疫苗进行免疫治疗，重点比较和研究单纯多肽致敏DC疫苗组和多肽致敏DC疫苗组联合CIK方案的差别，同时分析包括T淋巴细胞亚群增殖活化、Treg和肿瘤细胞凋亡等多项细胞与分子标志，深入研究免疫治疗的调节机制，实现为临床选择最佳免疫治疗方案的目标，对发展具有我国自主知识产权的肿瘤免疫治疗具有重要科学意义，对提高患者的生存率和生存质量具有临床实际意义。

Cancer immunotherapy has been receiving more and more attention in recent years, and has become a hot research topic. It plays a very important role in cancer assistant treatment. I'm personally in charge of this project. I have identified and reported PLAC1/CP1, a new class of colorectal cancer specific antigens in the international area, which induced a specific immune response in colorectal carcinoma patients. A positive correlation between this novel tumor antigen induced a specific immune response, and improved the survival rate of patients with colorectal carcinoma. It is an ideal target for CRC immunotherapy. I have identified four HLA-A*0201 restricted CD8 T cell epitopoes. This project through animal experimentation, and applying the new PLAC1/CP1 antigen pulsed DC vaccines to treat mice models with CRC. This project will focus our attention on studying the PLAC1/CP1 peptide pulsed DC vaccines, which united CIK, and the entire protein vaccine. We also detected the proliferation of activated T cell subsets, Treg and tumor cell apoptosis, through a variety of molecular immunology and molecular biology methods in order to deeply study immunotherapy mechanisms, and develop the best possible treatment programs. It has practical significance to provide a new safe and effective immunotherapy method, for improving a patient’s survival. At the same time, this study will have scientific significance for other types of malignant tumors... The research papers have been published in "Gastroenterology", "Immunogenetics", "Journal of gastroenterology" magazines, and other Chinese publications.